Progress in Neuro-Psychopharmacology and Biological Psychiatry
December 12, 2008
Sarah Durkin, Alison Prendergast, Andrew Harkin
Long-term serotonin (5-HT) neuronal loss is currently a major cause of concern associated with recreational use of the substituted amphetamine 3,4 methylenedioxymethamphetamine (MDMA; "Ecstasy"). Such loss may be problematic considering that psychiatric disorders such as depression and anxiety and responses to first line treatments for these disorders are associated with 5-HT. In this study the...
Toxicology
December 5, 2008
Helena Pontes, Carla Sousa, Renata Silva et al.
Ethanol is frequently consumed along with 3,4-methylenedioxymethamphetamine (MDMA; ecstasy). Since both compounds are hepatotoxic and are metabolized in the liver, an increased deleterious interaction resulting from the concomitant use of these two drugs seems plausible. Another important feature of MDMA-induced toxicity is hyperthermia, an effect known to be potentiated after continuous...
The International Journal of Neuropsychopharmacology
December 2, 2008
Sami Ben Hamida, Antoine Tracqui, Anne Pereira De Vasconcelos et al.
27 citations
Ecstasy (3,4-methylenedioxymethylamphetamine; MDMA) is a popular club drug often taken with ethanol (EtOH). We recently found EtOH potentiated the psychomotor effects of MDMA in rats. This potentiation could reflect pharmacodynamic or/and pharmacokinetic processes. To test the latter hypothesis, rats were injected i.p. with 6.6 or 10 mg/kg MDMA with or without 1.5 g/kg EtOH, and were killed at...
Neuropharmacology
December 2008
Matthew R. Skelton, Jessica A Able, Curtis E. Grace et al.
3,4-Methlylenedioxymethamphetamine (MDMA) administration (4 x 15 mg/kg) on a single day has been shown to cause path integration deficits in rats. While most animal experiments focus on single binge-type models of MDMA use, many MDMA users take the drug on a recurring basis. The purpose of this study was to compare the effects of repeated single-day treatments with MDMA (4 x 15 mg/kg) once...
Psychopharmacology
December 2008
Emily Joy Jaehne, Abdallah Salem, Rodney James Irvine
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") disrupts thermoregulation in rats and can lead to life-threatening hyperthermia in humans. MDMA administration can also lead to long-term neurotoxicity in animals and possibly humans. The purpose of the current study was to extend previous results on the acute effects of MDMA on behavioral thermoregulation to a repeated dosing regime,...
Yakugaku Zasshi
December 1, 2008
Kanako Satoh, Ryouichi Nonaka
4 citations
The Tokyo Metropolitan Government in Japan enacted an "Ordinance concerning the abuse prevention of the psychoactive drugs" in April 2006 that prohibited the manufacture, cultivation, sales, possession, use, etc., of these drugs. Therefore, we constructed a reproducible, simple, and small-scale determination method of the psychoactive drugs for the re-uptake and the release of monoamines...
BMC Public Health
November 15, 2008
P Schaalma Herman, Kok Gerjo, Peters Gjalt-Jorn
22 citations
Abstract Background Ecstasy (MDMA, 3, 4-methylenodioxymethamphetamine) use is widespread in the Netherlands, with a lifetime prevalence of 4.3%, and two-thirds of dance party visitors being ecstasy users. However, research into Dutch ecstasy use patterns is lacking. In addition, recent studies suggest that ecstasy users cease their use automatically, which implies that interventions would do...
Brain Research
November 6, 2008
Cynthia Marie‐claire, Nadia Benturquia, Ann Lundqvist et al.
3,4-methylenedioxymethamphetamine (MDMA) is a popular recreational drug that has rewarding properties in rodents but little is known about its effects at the cellular and molecular levels. We have previously shown that the ERK pathway is important for the regulation in gene expression observed in mice striatum after acute treatment with MDMA. Interestingly, three dual specificity phosphatases...
NMR in Biomedicine
November 4, 2008
Shane A. Perrine, Mark S. Michaels, Farhad Ghoddoussi et al.
39 citations
Abstract Despite the potential for deleterious (even fatal) effects on cardiac physiology, 3,4‐methylenedioxymethamphetamine (MDMA; ecstasy) abuse abounds driven mainly by its euphoric effects. Acute exposure to MDMA has profound cardiovascular effects on blood pressure and heart rate in humans and animals. To determine the effects of MDMA on cardiac metabolites in rats, MDMA (0, 5, or 10...
Journal of Psychopharmacology
November 2008
G Bedi, J Redman
Previous research has found relationships between self-rated memory and ecstasy use, such that heavier users report worse function. These findings have been interpreted in terms of objective memory capacity. However, research on metamemory suggests that self-reported memory may be only weakly related to objective function, with demographics, mood, and memory-related beliefs and feelings also...
International Journal of Legal Medicine
November 2008
Daniela Cerretani, Irene Riezzo, Anna Ida Fiaschi et al.
Experimental and clinical data indicate that 3,4-methylenedioxy-N-methylamphetamine (MDMA) abuse can produce significant cardiovascular toxicity. A mechanism may be a direct toxic effect of redox active metabolites of MDMA. To evaluate the effect of a single MDMA dose on cellular antioxidant defence system and to investigate the morphology in male albino rats, total glutathione (GSH), oxidised...
Clinical journal of the American Society of Nephrology : CJASN
November 2008
Garland A Campbell, Mitchell H Rosner
Ecstasy (MDMA, 3,4-methylenedioxymethamphetamine) is commonly used by college-aged individuals. Ecstasy leads to feelings of euphoria, emotional empathy, and increased energy. These effects come at a significant risk for complications. Ecstasy has been associated with acute kidney injury that is most commonly secondary to nontraumatic rhabdomyolysis but also has been reported in the setting of...
Neurotoxicology
November 2008
Katsutoshi Shioda, Koichi Nisijima, Tatsuki Yoshino et al.
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") is a widely used recreational drug. Despite an increase in the number of fatalities related to its use, no definite therapeutic method has been established thus far. In the present study, risperidone's ability to attenuate MDMA-induced hyperthermia and its mechanism of action were investigated in rats. The pharmacological effect of MDMA was...
Brain Research Bulletin
October 22, 2008
Allison A. Feduccia, Christine L. Duvauchelle
MDMA (3,4-methylenedioxymethamphetamine), also known as ecstasy, is a popular drug often taken in environments rich in audio and visual stimulation, such as clubs and dance parties. The present experiments were conducted to test the notion that auditory stimulation influences the rewarding effects of MDMA. In Experiment 1, a conditioned place preference (CPP) procedure was conducted in which...
Journal of Psychopharmacology
October 2, 2008
Sj Kish, Paul S. Fitzmaurice, Lj Chang et al.
31 citations
Evidence that the widely used methamphetamine analog MDMA (3,4-methylenedioxymethamphetamine, ecstasy) might damage brain serotonin neurones in humans is derived from imaging investigations showing variably decreased binding of radioligands to the serotonin transporter (SERT), a marker of serotonin neurones. However, in humans, it is not known whether low SERT binding reflects actual loss of...
Neuropharmacology
October 2008
Jack W Lipton, Emeline G Tolod, Valerie B Thompson et al.
The current study examined whether modest concentrations of MDMA could increase the survival and/or neurite outgrowth of fetal midbrain dopamine (DA) neurons in vitro since increased DA neurite outgrowth has been previously observed in vivo from prenatal exposure. MDMA concentrations in fetal brain were quantified to determine relevant in vivo concentrations to employ in vitro. A dose response...
Journal of Pharmacology and Experimental Therapeutics
October 2008
M A Starr, M E Page, B D Waterhouse
MDMA (3,4-methylenedioxymethamphetamine, Ecstasy) is reported to enhance tactile sensory perception, an effect that is believed to contribute to its popularity as a recreational drug. To date, no literature exists that addresses the neurophysiological mechanisms underlying the effects of MDMA on somatosensation. However, MDMA interactions with the serotonin transporter protein (SERT) are well...
Psychopharmacology
October 2008
Una D. Mccann, Zsolt Szabó, Melin Vranesic et al.
(+/-)3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") is a recreational drug and brain serotonin (5-HT) neurotoxin. Under certain conditions, MDMA can also damage brain dopamine (DA) neurons, at least in rodents. Human MDMA users have been found to have reduced brain 5-HT transporter (SERT) density and cognitive deficits, although it is not known whether these are related. This study sought...
Annals of the New York Academy of Sciences
October 1, 2008
Ronald L Cowan, Deanne M. Roberts, James M. Joers
26 citations
MDMA (3,4 methylenedioxymethamphetamine) has been used by millions of people worldwide as a recreational drug. The terms “MDMA” and “Ecstasy” are often used synonymously, but it is important to note that the purity of Ecstasy sold as MDMA is not certain. MDMA use is of public health concern, not so much because MDMA produces a common or severe dependence syndrome, but rather because rodent and...
Annals of the New York Academy of Sciences
October 1, 2008
Jerrold S. Meyer, Brian J. Piper, Valerie E. Vancollie
44 citations
Adult animals treated with high doses of MDMA (“ecstasy”) either on a single day or for several consecutive days show numerous behavioral changes as well as persistent reductions in brain serotonin (5‐HT) concentrations and 5‐HT transporter (SERT) protein expression. However, such dosing regimens do not adequately mimic the intermittent use patterns commonly seen in adolescent recreational...